Efficacy of prolonged valganciclovir therapy for congenital cytomegalovirus infection

Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings...

Full description

Saved in:
Bibliographic Details
Published in:Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2011, Vol.17 (4), p.538-540
Main Authors: Kashiwagi, Yasuyo, Kawashima, Hisashi, Nakajima, Junya, Ishida, Yu, Nishimata, Shigeo, Miyajima, Tasuku, Takekuma, Kouji, Hoshika, Akinori, Inoue, Naoki
Format: Article
Language:English
Subjects:
Antiviral Agents - administration & dosage
Brain - diagnostic imaging
Case Report
Congenital infection
Cytomegalovirus (CMV)
Cytomegalovirus - genetics
Cytomegalovirus - isolation & purification
Cytomegalovirus Infections - congenital
Cytomegalovirus Infections - diagnostic imaging
Cytomegalovirus Infections - drug therapy
Cytomegalovirus Infections - virology
DNA, Viral - blood
DNA, Viral - urine
Evoked Potentials, Auditory, Brain Stem
Ganciclovir - administration & dosage
Ganciclovir - analogs & derivatives
Hearing Loss - virology
Hematology, Oncology and Palliative Medicine
Humans
Infant, Newborn
Infant, Newborn, Diseases - diagnostic imaging
Infant, Newborn, Diseases - drug therapy
Infant, Newborn, Diseases - virology
Infectious Diseases
Magnetic resonance (MR) imaging
Magnetic Resonance Imaging
Male
Medical Microbiology
Medicine
Medicine & Public Health
Radiography
Valganciclovir (VGCV)
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract We report prolonged valganciclovir (VGCV) treatment of a symptomatic cytomegalovirus infection case. Automated auditory brainstem evoked response performed at 5 days of age revealed severe hearing impairment. Cranial magnetic resonance (MR) imaging at 11 days of age showed abnormal findings. At 5 weeks of age, VGCV was started. The viral load in blood cells, plasma, and urine decreased during the 6-week treatment. Because of improvement of hearing level and no adverse effects, VGCV was restarted for an additional 6 weeks. Neither the patient’s hearing impairment nor results of cranial MR imaging have become worse in 6 months. It is crucial to gather information from as many cases as possible treated with VGCV to establish a standard protocol for VGCV treatment.
ISSN:1341-321X
1437-7780
DOI:10.1007/s10156-010-0204-z